NONALCOHOLIC STEATOHEPATITIS
Clinical trials for NONALCOHOLIC STEATOHEPATITIS explained in plain language.
Never miss a new study
Get alerted when new NONALCOHOLIC STEATOHEPATITIS trials appear
Sign up with your email to follow new studies for NONALCOHOLIC STEATOHEPATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Common heart pill may fight deadly liver scarring
Disease control OngoingThis study is testing if lisinopril, a medication commonly used for high blood pressure, can help slow or prevent the progression of advanced fatty liver disease (NAFLD). It involves about 45 adults who already have significant liver scarring. Participants take the drug daily for…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New drug trial aims to halt scarring in advanced fatty liver disease
Disease control OngoingThis study is testing whether an investigational drug called efinopegdutide can help treat a serious form of fatty liver disease called MASH that has progressed to cause permanent scarring (cirrhosis). About 80 adults with this condition will receive either the drug or a placebo …
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
Hidden liver risk in diabetes: quick scan seeks silent scarring
Knowledge-focused OngoingThis study aims to find out how common fatty liver disease and serious liver scarring are in adults with type 1 diabetes. Researchers will screen over 500 patients using a quick, non-invasive scan and blood tests. The goal is to identify patients at high risk who may need to see …
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Sponsor: Joslin Diabetes Center • Aim: Knowledge-focused
Last updated Mar 19, 2026 14:55 UTC